Literature DB >> 22227650

Next-generation proteasome blockers promise safer cancer therapy.

Asher Mullard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22227650     DOI： 10.1038/nm0112-7a

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  Inhibition of proteasome deubiquitinating activity as a new cancer therapy.

Authors:  Pádraig D'Arcy; Slavica Brnjic; Maria Hägg Olofsson; Mårten Fryknäs; Kristina Lindsten; Michelandrea De Cesare; Paola Perego; Behnam Sadeghi; Moustapha Hassan; Rolf Larsson; Stig Linder
Journal:  Nat Med       Date:  2011-11-06       Impact factor: 53.440
  1 in total
  2 in total

1.  MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.

Authors:  Juan J Gu; Francisco J Hernandez-Ilizaliturri; Cory Mavis; Natalie M Czuczman; George Deeb; John Gibbs; Joseph J Skitzki; Ritesh Patil; Myron S Czuczman
Journal:  Anticancer Drugs       Date:  2013-11       Impact factor: 2.248

Review 2.  UBXD Proteins: A Family of Proteins with Diverse Functions in Cancer.

Authors:  Khosrow Rezvani
Journal:  Int J Mol Sci       Date:  2016-10-14       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.